Is Autophagy Always a Barrier to Cisplatin Therapy?
Abstract
Cisplatin has long been a first-line chemotherapeutic agent in the treatment of cancer, largely for solid tumors. During the course of the past two decades, autophagy has been identified in response to cancer treatments and almost uniformly detected in studies involving cisplatin. There has been increasing recognition of autophagy as a critical factor affecting tumor cell death and tumor chemoresistance. In this review and commentary, we introduce four mechanisms of resistance to cisplatin followed by a discussion of the factors that affect the role of autophagy in cisplatin-sensitive and resistant cells and explore the two-sided outcomes that occur when autophagy inhibitors are combined with cisplatin. Our goal is to analyze the potential for the combinatorial use of cisplatin and autophagy inhibitors in the clinic.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 17, 2022
- Source ID
- 10.3390/biom12030463
Entities
People
- David A. Gewirtz
- Jingwen Xu
Organizations
- United States Department of Defense